XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

Note 7. Stockholders’ Equity


Authorized Shares


The Company has 45,000,000 common shares authorized with a par value of $0.001 per share.


Common Stock


On January 8, 2020, the Company issued 50,000 shares of common stock to a former employee per the terms of a settlement agreement. 


On January 17, 2020, the Company issued 5,264 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 2,000 of such shares of Series A Convertible Preferred Stock.


On February 5, 2020, the Company issued 13,158 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 5,000 of such shares of Series A Convertible Preferred Stock. 


On February 21, 2020, the Company issued an aggregate of 100,000 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 38,000 of such shares of Series A Convertible Preferred Stock.


On February 22, 2020, the Company issued an aggregate of 39,474 shares of common stock to two holders of its Series A Convertible Preferred Stock upon the conversion of 15,000 of such shares of Series A Convertible Preferred Stock.


On February 26, 2020, the Company issued 19,737 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 7,500 of such shares of Series A Convertible Preferred Stock.


On March 12, 2020, the Company issued 16,667 shares of common stock to an employee pursuant to a vesting schedule.


Stock Incentive Plan 


The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2020 were:


   Warrant Grants   Stock Option Grants   Restricted Stock Units 
   Number of shares subject to warrants   Weighted-average exercise price per share   Number of shares subject to options   Weighted-average exercise price per share   Number of shares subject to restricted stock units   Weighted-average exercise price per share 
Balance at December 31, 2019   1,311,916   $9.35    338,595   $5.96    630,303   $          - 
Granted   -    -    -    -    395,000    - 
Exercised   -    -    -    -    -    - 
Cancelled/Forfeited   -    -    -    -    (250,000)   - 
Balance at March 31, 2020   1,311,916   $9.35    338,595   $5.96    775,303   $- 
Exercisable at March 31, 2020   1,311,916   $9.35    338,595   $5.96    

41,667

   $- 

As of March 31, 2020 and December 31, 2019, the total unrecognized expense for unvested stock options and restricted stock awards, net of actual forfeitures, was approximately $1.9 million and $3.2 million, respectively, to be recognized over a one-year period for restricted stock awards and one year for option grants from the date of grant. 


Stock-based compensation expense for the three months ended March 31, 2020 and 2019 was as follows:


   For the three months ended 
   March 31, 
   2020   2019 
Stock-based compensation expense  $367,600   $5,629,833 

Stock-based compensation expense categorized by the equity components for the three months ended March 31, 2020 and 2019 was as follows:


   For the three months ended 
   March 31, 
   2020   2019 
Common stock  $367,600   $257,885 
Stock option awards   -    49,018 
Transfer of common stock by founders to contractors   -    5,322,930 
Total  $367,600   $5,629,833